Literature DB >> 8397416

The influence of age on the development of the hepatitis B carrier state.

W J Edmunds1, G F Medley, D J Nokes, A J Hall, H C Whittle.   

Abstract

The relation between the age at infection with hepatitis B virus (HBV) and the development of the carrier state is examined by using data from a number of published and unpublished surveys. A remarkably consistent relation was found. Infants infected perinatally (within the first 6 months of life) were found to have a high probability of becoming carriers (0.885; 95% C.L. 0.84-0.93). Over the infant and early childhood age classes there was found to be a sharp decrease in the proportion of infections which lead to the carrier state. By adulthood (over 15 years) the probability of developing the carrier status was found to be about 0.1. A model was fitted to the data by using maximum likelihood, which provides a good empirical description of the observed data and can be used to predict the expected probability of developing the carrier state given the age at infection. It is postulated that, as a result of this rapid decline in the probability of becoming a carrier during early childhood, a mass childhood immunization campaign, which will tend to postpone the average age at infection in the unvaccinated community, will have a disproportionately large impact on the rate of generation of new carriers.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397416     DOI: 10.1098/rspb.1993.0102

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  100 in total

1.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

Review 2.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

3.  The dynamics of hepatitis B virus infection.

Authors:  R J Payne; M A Nowak; B S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  Optimal control for an age-structured model for the transmission of hepatitis B.

Authors:  Ramses Djidjou Demasse; Jean-Jules Tewa; Samuel Bowong; Yves Emvudu
Journal:  J Math Biol       Date:  2015-12-16       Impact factor: 2.259

5.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Authors:  Yanbing Zeng; Mingliang Luo; Jianlin Lin; Hanqing He; Xuan Deng; Shuyun Xie; Ya Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

6.  Hepatitis B vaccination.

Authors:  Andrew J Pollard
Journal:  BMJ       Date:  2007-11-10

7.  Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants.

Authors:  Charles S Chasela; Athena P Kourtis; Patrick Wall; Jan Drobeniuc; Caroline C King; Hong Thai; Eyasu H Teshale; Mina Hosseinipour; Sascha Ellington; Mary B Codd; Denise J Jamieson; Rod Knight; Patricia Fitzpatrick; Saleem Kamili; Irving Hoffman; Dumbani Kayira; Noel Mumba; Deborah D Kamwendo; Francis Martinson; William Powderly; Chong-Gee Teo; Charles van der Horst
Journal:  J Hepatol       Date:  2013-11-06       Impact factor: 25.083

8.  Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.

Authors:  Yuanxi Jia; Li Li; Fuqiang Cui; Dongliang Zhang; Guomin Zhang; Fuzhen Wang; Xiaohong Gong; Hui Zheng; Zhenhua Wu; Ning Miao; Xiaojin Sun; Li Zhang; Jingjing Lv; Feng Yang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  Cancer of childhood in sub-Saharan Africa.

Authors:  Cristina Stefan; Freddie Bray; Jacques Ferlay; Biying Liu; D Maxwell Parkin
Journal:  Ecancermedicalscience       Date:  2017-07-28

10.  Hepatitis B in Pregnancy.

Authors:  Tram T Tran
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.